Fig. 4From: Early onset of effect following galcanezumab treatment in patients with previous preventive medication failuresEstimated mean percentage of patients with ≥50%, ≥75%, and 100% reduction from baseline in monthly migraine headache days at months 1–3. * p < 0.05, ** p < 0.01, *** p ≤ 0.0001 vs placebo. SE standard errorBack to article page